Protecting the endothelium: A new focus for management of chronic kidney disease

Hemodialysis International

Volumn 10, Issue 1, 2006, Pages 42-48

  Diaz Buxo, Jose A ^a,c   Woods, H Feidhlim ^b  

^a FRESENIUS MEDICAL CARE NORTH AMERICA   (United States)

^b Fresenius Medical Care Asia Pacific   (Hong Kong)

^c NONE   (United States)

Author keywords

Cardiovascular disease; Chronic kidney disease; Endothelial dysfunction; Hemodialysis; Inflammation; Oxidative stress

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIMIMETIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FREE RADICAL; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; NITRIC OXIDE; PHOSPHATE BINDING AGENT; VITAMIN D DERIVATIVE;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DIALYSATE; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM INJURY; EVIDENCE BASED PRACTICE; HEMODIALYSIS PATIENT; HIGH RISK PATIENT; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPERTENSION; INFLAMMATION; LOW DRUG DOSE; METABOLIC DISORDER; NEPHROLOGIST; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; TREATMENT OUTCOME; UREMIA; VASCULAR DISEASE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; ENDOTHELIUM, VASCULAR; FREE RADICALS; HUMANS; INFLAMMATION; KIDNEY DISEASES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS;

EID: 33144477390     PISSN: 14927535     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2006.01173.x     Document Type: Article

References (40)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998; 32:S112-S119.
2. U.S. Renal Data System. Excerpts from the USRDS 2004 Annual Data Report. Am J Kidney Dis. 2005; 45(Suppl 1):S1-S280.
3. Levey AS, Eknoyan G. Cardiovascular disease in chronic renal disease. Nephrol Dial Transplant. 1999; 14:828-833.
4. Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 1995; 47:186-192.
5. Zocalli C. Cardiorenal risk as a new frontier of nephrology: Research needs and areas for intervention. Nephrol Dial Transplant. 2002; 17(Suppl 11):50-54.
6. Vanholder R, Mazzy Z for the European Uremic Toxin Work Group (EUTox) et al. Chronic kidney disease as a cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant. 2005; 20:1048-1056.
7. Morris ST, Jardine AG. The vascular endothelium in chronic renal failure. J Nephrol. 2000; 13:96-105.
8. Nedeljkovic ZS, Gakce N, Loscalzo J. Mechanisms of oxidative stress and vascular dysfunction. Postgrad Med J. 2003; 79:195-199.
9. Kone BC. Nitric oxide in renal health and disease. Am J Kidney Dis. 1997; 30:311-333.
10. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: A review. Diabetologia. 2001; 44:129-146.
11. Weiss MF, Erhard P, Kader-Attia FA, et al. Mechanisms for the formation of glycoxidation products in end-stage renal disease. Kidney Int. 2000; 57:2571-2585.
12. Zoccali C, Mallamaci F, Tripepi G. Inflammation and atherosclerosis in end-stage renal disease. Blood Purif. 2003; 21:29-36.
13. De Deyn PP, Vanholder R, D'Hooge R. Nitric oxide in uremia: Effects of several potentially toxic guanidino compounds. Kidney Int. 2003; 63(Suppl 84):S25-S28.
14. Stenvinkel P, Alvestrand A. Inflammation in end-stage renal disease: Sources, consequences, and therapy. Sem Dial. 2002; 15:329-337.
15. Halliwell B, Gutteridge JM. Free Radicals in Biology and Medicine. 3rd ed. Oxford: Oxford Science Publications (OUP); 1999.
16. Amann K, Ritz C, Adamczak M, Ritz E. Why is coronary heart disease of uraemic patients so frequent and so devastatine. Nephrol Dial Transplant. 2003; 18:631-640.
17. Himmelfarb J, Stenvinkel P, Ikizler A, Hakim R. The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002; 62:1524-1538.
18. Szmitko PE, Wang CH, Weisel RD, de Almeida JR, Anderson TJ, Verma S. New markers of inflammation and endothelial cell activation, Part I. Circulation. 2003; 108:1917-1923.
19. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002; 105:1135-1143.
20. Herbrig K, Pistrosch F, Oelschlaegel U, et al. Increased total number but impaired migratory activity and adhesion of endothelial progenitor cells in patients on long-term hemodialysis. Am J Kidney Dis. 2004; 44:840-849.
21. Al Ziyad A, Edwards JC. Vascular biology in uremia: Insights into novel mechanisms of vascular injury. Adv Chronic Kidney Disease. 2004; 11:310-318.
22. Nickenig G, Harrison DG. The AT1-type angiotensin receptor in oxidative stress and atherogenesis: Part I: Oxidative stress and atherogenesis. Circulation. 2002; 105:393-396.
23. Kosch M, Levers A, Fobker M, et al. Dialysis filter type determines the acute effect of haemodialysis on endothelial function and oxidative stress. Nephrol Dial Transplant. 2003; 18:1370-1375.
24. Ward RA, Ouseph R, McLeish KR. Effects of high-flux hemodialysis on oxidant stress. Kidney Int. 2003; 63: 353-359.
25. Floridi A, Antolini F, Galli F, Fagugli RM, Floridi E, Buoncristiani U. Daily haemodialysis improves indices of protein glycation. Nephrol Dial Transplant. 2002; 17:871-878.
26. Ross R. Atherosclerosis: An inflammatory disease. N Eng J Med. 1999; 340:115 126.
27. Lerman A, Zeiher AM. Endothelial function: Cardiac events. Circulation. 2005; 111:363-368.
28. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Heenekens CH. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Eng J Med. 1979; 336:973-979.
29. Pecoits-Filho R, Lindholm B, Axelsson J, Stenvinkel P. Update on interleukin-6 and its role in chronic renal failure. Nephrol Dial Transplant. 2003; 18:1042-1045.
30. Kaysen GA. The microinflammatory state in uremia: Causes and potential consequences. J Am Soc Nephrol. 2001; 12:1549-1557.
31. Block GA, Port FK. Reevaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change of management. Am J Kidney Dis. 2000; 35:1226-1237.
32. Ketteler M, Warmer C, Metzger T, et al. Deficiencies of calcium-regulatory proteins in dialysis patients: A novel concept of cardiovascular calcification in uremia. Kidney Int. 2003; 63(Suppl 84):S84-S87.
33. Giannini S, Serio M, Galli A. Pleiotropic effects of thiazolidinediones: Taking a look beyond antidiabetic activity. J Endocrinol Invest. 2004; 27:982-991.
34. Koh KK, Quon MJ, Han SH, et al. Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. Hypertension. 2005; 45:1088-1093.
35. Haendeler J, Hoffmann J, Zeiher AM, Dimmeler S. Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: A novel vasculoprotective function of statins. Circulation. 2004; 110:856-861.
36. Collaborative Group of the Primary Prevention Project (PPP). Low-dose aspirin and vitamin E in people at cardiovascular risk: A randomised trial in general practice. Lancet. 2001; 357:87-95.
37. Guan Y. Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome. J Am Soc Nephrol. 2004; 15:2801-2815.
38. Behdad A, Al Haydar A, Vinen K, Goldsmith DJA. From Finland to Fatland: Beneficial effects of statins for patients with chronic kidney disease. J Am Soc Nephrol. 2004; 15:2161-168.
39. Yao Q, Lindholm B, Stenvinkel P. Inflammation as a cause of malnutrition, atherosclerotic cardiovascular disease, and poor outcome in hemodialysis patients. Hemodialysis Int. 2004; 8:118-129.
40. Williams JD, Topley N, Craig KJ, et al. The euro-balance trial: The effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int. 2004; 66:408-418.